Bio-Techne (NASDAQ: TECH) reported Q3 EPS of $2.14, $0.14 better than the analyst estimate of $2.00. Revenue for the quarter came in at $290.4 million versus the consensus estimate of $279.27 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.